Why the study?
How do five major guidelines for statin use in primary prevention compare in terms of eligibility and estimated ASCVD events prevented in a contemporary general population?
Population
45,750 Danish persons aged 40 to 75 years who did not use statins and did not have ASCVD at baseline
Comparison
Statin eligibility according to five major… vs Comparison among the five guidelines
Design
Cohort
Follow-up
10 years
Key result
Applying the CCS and ACC/AHA guidelines for primary prevention of ASCVD was estimated to prevent 34% of events over 10 years, compared with 32% for NICE, 27% for USPSTF, and 13% for ESC/EAS.
Authors
Loading...
Broader statin guidelines (CCS/ACC/AHA) may avert more events; leaves open optimal thresholds without randomized confirmation.
Observational (n=45,750)
How do five major guidelines for statin use in primary prevention compare in terms of eligibility and estimated ASCVD events prevented in a contemporary general population?
Guidelines recommending broader statin eligibility for primary prevention (like CCS and ACC/AHA) are estimated to prevent more ASCVD events than more restrictive guidelines (like ESC/EAS).
Mortensen et al. (2018) conducted an observational in Atherosclerotic cardiovascular disease (ASCVD) (n=45,750). Statin eligibility guidelines (CCS, ACC/AHA, NICE, USPSTF, ESC/EAS) was evaluated on Estimated percentage of ASCVD events that could have been prevented by using statins for 10 years. Applying the CCS and ACC/AHA guidelines for primary prevention of ASCVD was estimated to prevent 34% of events over 10 years, compared with 32% for NICE, 27% for USPSTF, and 13% for ESC/EAS.